Last reviewed · How we verify

NCT04679961

Deep Learning on 3D Cellular-resolution Tomogram

Completed Last updated 17 March 2023
What this trial tests

trial testing ApolloVue® S100 Image System (Apollo Medical Optics) in Skin Diseases in 107 participants. Completed in 14 December 2022.

Timeline
21 December 2020
Primary endpoint
14 December 2022
14 December 2022

Quick facts

Lead sponsorMackay Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment107
Start date21 December 2020
Primary completion14 December 2022
Estimated completion14 December 2022
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Mackay Memorial Hospital

Who can join

20 and older, any sex, with Skin Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Skin biopsy is the main method to diagnose skin tumors, skin inflammation, and pigmented diseases. However, biopsy is an invasive method that can cause wounds and scars. Optical coherent tomography (OCT) technology is a fast, non-invasive, non-radioactive, and label-free imaging method. This technology generates real-time images of living tissue by detecting the variations in the refractive indexes of various components in soft tissues. Recently, there is a breakthrough progress that the newly designed ultrahigh resolution OCT can provide in vivo cellular resolution similar to histopathological sections in the high magnification. In our previous clinical trial "Early feasibility study: application of OCT imaging in dermatology" (approved by IRB of MacKay Memorial Hospital, no. 17CT062Be), it showed characteristic features of different skin inflammatory diseases and tumors can be distinguished successfully in tomograms. There were no adverse event or serious adverse event in this trial. Artificial intelligence technologies have been used widely in the image analysis in recent years. Hence, we aim to collect OCT tomograms of common skin inflammatory diseases, skin tumors, and pigmented diseases, and compare with normal skin for machine learning. We expect the integration of tomograms with deep learning artificial intelligence may assist identifying histological features in these images and provide new alternative way for non-invasive diagnosis in dermatology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ApolloVue® S100 Image System (Apollo Medical Optics)

Trials testing the same drug.

Other recruiting trials for Skin Diseases

Currently open trials in the same condition.

Other Mackay Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04679961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing